Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

47583

Sigma-Aldrich

Fmoc-Lys(Alloc)-OH

≥95.0% (HPLC), for peptide synthesis

Synonym(s):

Nα-Fmoc-Nε-Alloc-L-lysine

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C25H28N2O6
CAS Number:
Molecular Weight:
452.50
Beilstein/REAXYS Number:
5893081
MDL number:
UNSPSC Code:
12352209
eCl@ss:
32160406
PubChem Substance ID:
NACRES:
NA.26

product name

Fmoc-Lys(Alloc)-OH, ≥95.0% (HPLC)

Quality Level

assay

≥95.0% (HPLC)

form

powder

optical activity

[α]20/D −12±1°, c = 1% in DMF

reaction suitability

reaction type: Fmoc solid-phase peptide synthesis

technique(s)

NMR: suitable

color

beige

application(s)

peptide synthesis

functional group

Fmoc

storage temp.

2-8°C

SMILES string

OC(=O)[C@H](CCCCNC(=O)OCC=C)NC(=O)OCC1c2ccccc2-c3ccccc13

InChI

1S/C25H28N2O6/c1-2-15-32-24(30)26-14-8-7-13-22(23(28)29)27-25(31)33-16-21-19-11-5-3-9-17(19)18-10-4-6-12-20(18)21/h2-6,9-12,21-22H,1,7-8,13-16H2,(H,26,30)(H,27,31)(H,28,29)/t22-/m0/s1

InChI key

OJBNDXHENJDCBA-QFIPXVFZSA-N

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Mireia Hoyos-Nogués et al.
ACS applied materials & interfaces, 9(26), 21618-21630 (2017-06-09)
In dentistry and orthopedics, it is well accepted that implant fixation is a major goal. However, an emerging concern is bacterial infection. Infection of metallic implants can be catastrophic and significantly reduce patient quality of life. Accordingly, in this work
Petro P Czupiel et al.
Journal of controlled release : official journal of the Controlled Release Society, 305, 210-219 (2019-05-10)
Currently, there are limited treatment options for multi-drug resistant breast cancer. Lipid-modified cationic peptides have the potential to reach the mitochondria, which are attractive targets for the treatment of multi-drug resistant (MDR) breast cancer; yet, little is known about their

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service